Press / media

As an institution of application-oriented research, the Fraunhofer Institute for Cell Therapy and Immunology IZI attaches great importance to informing customers and the public.

25.10.2022

International research team elucidates molecular structure of Meprin alpha

Together with colleagues from Monash University (Melbourne, Australia) and other institutions, Fraunhofer IZI researchers have elucidated the helical ultrastructure of the metalloprotease Meprin alpha. The results have now been published in the journal Nature Communications.
Read more

6.9.2022

Roadmap for future production of sufficient product numbers of cell-based cancer drugs

Cell-based immunotherapies, such as CAR T cell therapy, are effective means of treating cancer. However, technological advances in various disciplines are needed to meet the rapidly growing demand for such novel drugs. Researchers from the Fraunhofer Institute for Cell Therapy and Immunology now summarize the current state of research and discuss possible solutions to overcome biological and technical hurdles in their recent article "Potential solutions for manufacture of CAR T cells in cancer immunotherapy" published in the journal Nature Communications.
Read more

5.9.2022

REMEDi4ALL, an ambitious EU-funded research initiative, launches to drive forward the repurposing of medicines in Europe

The EU-funded project REMEDi4ALL willl make a major leap forward in drug repurposing, or finding new therapeutic option for existing drugs, in areas where there are high unmet medical needs. The 3 Fraunhofer institutes participating, for Translational Medicine and Pharmacology ITMP, for Cell Therapy and Immunology IZI and for Algorithms and Scientific Computing SCAI, combine expertise in the realization of in-silico and in-vitro driven drug repurposing programs, the design of predictive in vivo models, the execution of clinical trials and algorithm development for the analysis of drug discovery data.
Read more

7.6.2022

Preclinical testing of a ATMP for the treatment of knee cartilage damage completed

The Fraunhofer Institute for Cell Therapy and Immunology IZI is certified as a GLP test facility. Most recently, the institute conducted, among other things, a preclinical study to test the safety of an ATMP for the treatment of cartilage damage to the knee. An advanced therapy medicinal product (ATMP) developed by BioPlanta GmbH was subjected to extensive testing under GLP conditions with regard to its potential undesirable biodistribution and tumorigenicity.
Read more

Archive news and press releases

RSS Newsfeed

Get the latest news about the Fraunhofer IZI. Through our RSS-feed you have the opportunity to follow all our press releases and receive them right when they are published.

Social media

 

Media library

 

Publications

 

Events